Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMGL NASDAQ:BRTX NYSE:CCM NASDAQ:OPGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMGLBasel Medical Group$2.02-7.8%$2.62$0.91▼$9.40$40.42MN/A6.71 million shs99,447 shsBRTXBiorestorative Therapies$1.41-4.1%$1.66$1.21▼$2.55$11.03M76.73104,921 shs31,960 shsCCMConcord Medical Services$6.00+20.5%$6.06$3.80▼$10.77$21.62M-0.9418,233 shs24,111 shsOPGNOpGen$0.04$3.99$0.04▼$5.25$396K-1.668,849 shs1 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMGLBasel Medical Group-7.76%-10.22%+16.09%-51.56%+201,999,900.00%BRTXBiorestorative Therapies-4.08%-12.96%-11.32%-23.37%-7.84%CCMConcord Medical Services+17.76%+9.89%+6.76%-10.04%-24.43%OPGNOpGen0.00%+0.77%-99.17%-99.24%-98.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMGLBasel Medical GroupN/AN/AN/AN/AN/AN/AN/AN/ABRTXBiorestorative Therapies3.5106 of 5 stars3.55.00.00.00.03.30.6CCMConcord Medical Services1.6858 of 5 stars0.05.00.00.02.81.70.6OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMGLBasel Medical Group 0.00N/AN/AN/ABRTXBiorestorative Therapies 3.00Buy$18.001,176.60% UpsideCCMConcord Medical Services 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMGLBasel Medical Group$10.00M3.73N/AN/AN/A∞BRTXBiorestorative Therapies$400K26.44N/AN/A$1.23 per share1.15CCMConcord Medical Services$52.60M0.50N/AN/A$51.05 per share0.12OPGNOpGen$2.67M0.15N/AN/A($11.55) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMGLBasel Medical GroupN/AN/A0.00∞N/AN/AN/AN/AN/ABRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)CCMConcord Medical Services-$42.23MN/A0.00∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%N/ALatest BRTX, OPGN, BMGL, and CCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BRTXBiorestorative Therapies-$0.41N/AN/AN/A$0.34 millionN/A5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMGLBasel Medical GroupN/AN/AN/AN/AN/ABRTXBiorestorative TherapiesN/AN/AN/AN/AN/ACCMConcord Medical ServicesN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMGLBasel Medical GroupN/AN/AN/ABRTXBiorestorative TherapiesN/A2.242.24CCMConcord Medical Services1.670.460.45OPGNOpGenN/A5.455.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMGLBasel Medical GroupN/ABRTXBiorestorative Therapies69.38%CCMConcord Medical ServicesN/AOPGNOpGen2.68%Insider OwnershipCompanyInsider OwnershipBMGLBasel Medical GroupN/ABRTXBiorestorative Therapies25.50%CCMConcord Medical Services46.50%OPGNOpGen43.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMGLBasel Medical Group3618.46 millionN/AN/ABRTXBiorestorative Therapies77.50 million5.59 millionNot OptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionableBRTX, OPGN, BMGL, and CCM HeadlinesRecent News About These CompaniesOpGen Forms Joint Venture with European BankMay 29, 2025 | tipranks.comOpGen Delays 10-Q Filing Amid Operational ChallengesMay 16, 2025 | tipranks.comOpGen Inc ziet aanzienlijke aankoop van aandelen door AEI Capital LtdDecember 11, 2024 | nl.investing.comOpGen Inc aandeelhouder AEI Capital Ltd verhoogt belang met aankoop van €1,9 biljoenDecember 10, 2024 | nl.investing.comOpGen Appoints New COO and Company SecretaryDecember 6, 2024 | tipranks.comOpGen (OTC:OPGN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comOPGN Stock Earnings: OpGen Reported Results for Q2 2024August 21, 2024 | investorplace.comOPGN Stock Earnings: OpGen Reported Results for Q1 2024July 8, 2024 | investorplace.comOPGN Stock Earnings: OpGen Meets Revenue for Q4 2023June 5, 2024 | investorplace.comOpgen Inc (NASDAQ:OPGN) stock Posted Gross Margin of 6.62 percent in Last Year: Is Justifiable?May 27, 2024 | bovnews.comBOpGen, Inc.: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 25, 2024 | finanznachrichten.deOpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 24, 2024 | globenewswire.comOpGen to Execute 1-for-10 Reverse Stock SplitMay 16, 2024 | 360dx.com3OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | finanznachrichten.deOpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | globenewswire.comOpGen, Inc. (OPGN) stock price, news, quote & history – Yahoo FinanceMay 4, 2024 | uk.finance.yahoo.comOpGen, Inc.: OpGen Provides Update on Business Operations and Strategic OpportunitiesApril 30, 2024 | finanznachrichten.deOpGen Provides Update on Business Operations and Strategic OpportunitiesApril 29, 2024 | globenewswire.comOpGen CEO David Lazar buys additional shares worth $150kApril 27, 2024 | investing.comOpGen, Inc.: OpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 26, 2024 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRTX, OPGN, BMGL, and CCM Company DescriptionsBasel Medical Group NASDAQ:BMGL$2.02 -0.17 (-7.76%) As of 08/1/2025 04:00 PM EasternBasel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.Biorestorative Therapies NASDAQ:BRTX$1.41 -0.06 (-4.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.42 +0.01 (+0.71%) As of 08/1/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Concord Medical Services NYSE:CCM$6.00 +1.02 (+20.48%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$6.23 +0.23 (+3.83%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.OpGen NASDAQ:OPGN$0.04 0.00 (0.00%) As of 07/31/2025OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
